Tamibarotene

DB04942InvestigationalSmall molecule

Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United...

Mechanism: Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR).
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (unspecified).Curator reviewed
Formula / weight: C₂₂H₂₅NO₃ · 351.4388 g/mol (avg)
Also known as: retinobenzoic acid
Code names: AM-80 · NSC-608000 · SY-1425

Resolves to

Compound

UNII08V52GZ3H9CAS94497-51-5ChEMBLCHEMBL25202ChEBI32181PubChem108143KEGGD01418

Clinical / RWD

PharmGKBPA164743464

Structure

InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-NSMILESCC1(C)CCC(C)(C)C2=C1C=CC(NC(=O)C1=CC=C(C=C1)C(O)=O)=C2

Targets

P10276RARAP10826RARB

What you can answer from here — as of April 29, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

27+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tamibarotene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account